secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001737287-25-000087
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Q2 net loss $50.9M; highlights ALPHA3 trial progress and ALLO-329 autoimmune initiation
--------------------------------------------------------------------------------

- Net loss of $50.9M ($0.23/share) for Q2 2025; cash and investments $302.6M as of June 30, 2025.
- Pivotal ALPHA3 trial for cema-cel in LBCL proceeding as randomized two-arm study; futility analysis on track for 1H 2026.
- Phase 1 RESOLUTION trial with ALLO-329 initiated in rheumatology autoimmune diseases; proof-of-concept data expected 1H 2026.
- ALLO-316 completed Phase 1b enrollment in RCC; FDA aligned on pivotal trial design, partnership discussions possible.
- Cash runway projected into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP OpEx ~$230M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728725000087/0001737287-25-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728725000087/allo-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001737287-25-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer